Indivior (NASDAQ:INDV) Releases Earnings Results

Indivior (NASDAQ:INDV) released its earnings results on Thursday. The company reported $0.32 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.32, Zacks reports. Indivior had a negative net margin of 0.17% and a negative return on equity of 351.08%. Indivior updated its FY 2025 guidance to EPS.

Indivior Price Performance

Shares of Indivior stock traded down $1.64 on Thursday, reaching $9.27. 1,455,099 shares of the company traded hands, compared to its average volume of 1,147,317. Indivior has a 52 week low of $7.33 and a 52 week high of $23.22. The company has a 50 day moving average of $11.56 and a 200 day moving average of $10.89. The firm has a market capitalization of $1.28 billion, a PE ratio of -231.32 and a beta of 0.73.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on the stock. Rodman & Renshaw assumed coverage on shares of Indivior in a research report on Tuesday, January 28th. They issued a “buy” rating and a $16.00 price objective for the company. RODMAN&RENSHAW raised shares of Indivior to a “strong-buy” rating in a research report on Tuesday, January 28th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $16.00 price objective (up from $15.00) on shares of Indivior in a research report on Friday, October 25th.

Indivior Company Profile

Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.